ATGAM General Investigation

Pfizer

Status: Active, not recruiting

Conditions: Aplastic Anemia

Treatments: Drug: Anti-human thymocyte immunoglobulin, equine

Study type: Observational

Funder types: Industry

Identifiers

NCT06039020

B5411004

Details and patient eligibility

About

The objective of this study is to confirm the safety of ATGAM in patients with moderate to severe aplastic anemia under the actual use in Japan.

The registration criteria is patients with moderate to severe aplastic anemia who receive ATGAM.

The observation period is 24 weeks (6 months) from the start of administration (Day 1). However, in cases where treatment has been completed or discontinued less than 24 weeks after the start of administration, observation is continued until completion (discontinuation) of treatment.

Enrollment: 1 patient

Sex: All

Ages: Under 99 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with moderate to severe aplastic anemia who receive ATGAM

Exclusion criteria

• No exclusion criteria is set out in this study.

Trial design

1 participants in 1 patient group

Anti-human thymocyte immunoglobulin, equine

Description:

Patients with moderate to severe aplastic anemia who receive ATGAM (Anti-human thymocyte immunoglobulin, equine)

Treatment:

Drug: Anti-human thymocyte immunoglobulin, equine